BRPI1006869A2 - estimuladores de sgc ou ativadores da sgc em combinação com inibidores da pde5 para o tratamento de disfunção erétil - Google Patents
estimuladores de sgc ou ativadores da sgc em combinação com inibidores da pde5 para o tratamento de disfunção erétilInfo
- Publication number
- BRPI1006869A2 BRPI1006869A2 BRPI1006869A BRPI1006869A BRPI1006869A2 BR PI1006869 A2 BRPI1006869 A2 BR PI1006869A2 BR PI1006869 A BRPI1006869 A BR PI1006869A BR PI1006869 A BRPI1006869 A BR PI1006869A BR PI1006869 A2 BRPI1006869 A2 BR PI1006869A2
- Authority
- BR
- Brazil
- Prior art keywords
- sgc
- treatment
- combination
- erectile dysfunction
- pde5 inhibitors
- Prior art date
Links
- 208000010228 Erectile Dysfunction Diseases 0.000 title 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
- 201000001881 impotence Diseases 0.000 title 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 title 1
- 229940127296 soluble guanylate cyclase stimulator Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09000619 | 2009-01-17 | ||
| EP09002177 | 2009-02-17 | ||
| PCT/EP2010/000029 WO2010081647A2 (en) | 2009-01-17 | 2010-01-07 | Sgc stimulators of sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1006869A2 true BRPI1006869A2 (pt) | 2016-03-15 |
Family
ID=42153923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1006869A BRPI1006869A2 (pt) | 2009-01-17 | 2010-01-07 | estimuladores de sgc ou ativadores da sgc em combinação com inibidores da pde5 para o tratamento de disfunção erétil |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20120022028A1 (pt) |
| EP (1) | EP2387404B1 (pt) |
| JP (1) | JP5780430B2 (pt) |
| KR (1) | KR20110117655A (pt) |
| CN (1) | CN102316870A (pt) |
| AU (1) | AU2010205931A1 (pt) |
| BR (1) | BRPI1006869A2 (pt) |
| CA (1) | CA2749730C (pt) |
| CL (1) | CL2011001712A1 (pt) |
| EA (1) | EA201170942A1 (pt) |
| ES (1) | ES2493718T3 (pt) |
| IL (1) | IL213857A0 (pt) |
| MA (1) | MA32967B1 (pt) |
| MX (1) | MX2011007515A (pt) |
| SG (1) | SG172841A1 (pt) |
| SV (1) | SV2011003973A (pt) |
| TN (1) | TN2011000349A1 (pt) |
| TW (1) | TW201036971A (pt) |
| WO (1) | WO2010081647A2 (pt) |
| ZA (1) | ZA201105085B (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011095553A1 (en) * | 2010-02-05 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft | Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction |
| CN103038232B (zh) | 2010-05-26 | 2016-01-20 | 阿德弗里奥药品有限责任公司 | 单独的和与PDE5抑制剂相组合的sGC刺激剂、sGC活化剂用于治疗系统性硬化症(SSc)的用途 |
| EP2687210A1 (de) * | 2010-06-25 | 2014-01-22 | Bayer Intellectual Property GmbH | Verwendung von Stimulatoren und Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Sichelzellanämie und Konservierung von Blutersatzstoffen |
| WO2012122340A1 (en) | 2011-03-10 | 2012-09-13 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| EP2766360B1 (en) | 2011-08-12 | 2017-07-12 | Boehringer Ingelheim International GmbH | Soluble guanylate cyclase activators |
| KR101960100B1 (ko) * | 2011-12-08 | 2019-03-19 | 에스케이케미칼 주식회사 | 미로데나필 또는 이의 약학적으로 허용 가능한 염을 함유하는 구강 투여용 필름 |
| HUE046996T2 (hu) * | 2012-09-07 | 2020-04-28 | Boehringer Ingelheim Int | Alkoxi-pirazolilok, mint oldható guanilát cikláz inhibitorok |
| WO2015011086A1 (en) | 2013-07-25 | 2015-01-29 | Bayer Pharma Aktiengesellschaft | Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis |
| WO2015089105A1 (en) | 2013-12-09 | 2015-06-18 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| CN106459017B (zh) | 2014-07-22 | 2020-07-17 | 勃林格殷格翰国际有限公司 | 作为可溶性鸟苷酸环化酶活化剂的杂环羧酸 |
| KR20180081535A (ko) | 2015-11-16 | 2018-07-16 | 토파두르 파마 아게 | 포스포디에스테라제 억제제로서 2-페닐-3,4-디하이드로피롤로[2,1-f][1,2,4]트리아지논 유도체 및 이의 용도 |
| IL269835B (en) | 2017-05-22 | 2022-08-01 | Topadur Pharma Ag | Novel dual-acting soluble guanylate cyclase activators and phosphodiesterase inhibitors and their uses |
| CN113166157A (zh) | 2018-11-28 | 2021-07-23 | 托帕杜制药公司 | 新型双作用模式可溶性鸟苷酸环化酶活化剂和磷酸二酯酶抑制剂及其用途 |
| CN110305837A (zh) * | 2019-06-05 | 2019-10-08 | 西北师范大学 | 磷酸二酯酶5活性抑制剂作为诱导斑马鱼卵母细胞成熟的催熟剂的应用 |
| WO2021245192A1 (en) | 2020-06-04 | 2021-12-09 | Topadur Pharma Ag | Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB371800A (en) | 1929-10-21 | 1932-04-28 | Willem Zaadnoordijk | A process of filtering gases and fogs |
| GB369003A (en) | 1931-03-25 | 1932-03-17 | Richard Henry Sansome | Improvements in fire extinguishing fluids |
| CN1332943C (zh) * | 1998-07-08 | 2007-08-22 | 萨诺费－阿文蒂斯德国有限公司 | 硫取代的磺酰基氨基羧酸n－芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂 |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| US20100144864A1 (en) * | 2007-04-05 | 2010-06-10 | Ironwood Pharmaceuticals, Inc. | Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders |
| AU2008250643A1 (en) * | 2007-05-12 | 2008-11-20 | Bayer Schering Pharma Aktiengesellschaft | sGC stimulators, sGC activators and combinations for the treatment of urological disorders |
-
2010
- 2010-01-07 BR BRPI1006869A patent/BRPI1006869A2/pt not_active Application Discontinuation
- 2010-01-07 ES ES10700938.3T patent/ES2493718T3/es active Active
- 2010-01-07 JP JP2011545666A patent/JP5780430B2/ja not_active Expired - Fee Related
- 2010-01-07 MX MX2011007515A patent/MX2011007515A/es not_active Application Discontinuation
- 2010-01-07 KR KR1020117016559A patent/KR20110117655A/ko not_active Application Discontinuation
- 2010-01-07 SG SG2011048840A patent/SG172841A1/en unknown
- 2010-01-07 US US13/144,929 patent/US20120022028A1/en not_active Abandoned
- 2010-01-07 MA MA34016A patent/MA32967B1/fr unknown
- 2010-01-07 CN CN2010800047775A patent/CN102316870A/zh active Pending
- 2010-01-07 EP EP10700938.3A patent/EP2387404B1/en active Active
- 2010-01-07 EA EA201170942A patent/EA201170942A1/ru unknown
- 2010-01-07 AU AU2010205931A patent/AU2010205931A1/en not_active Abandoned
- 2010-01-07 WO PCT/EP2010/000029 patent/WO2010081647A2/en active Application Filing
- 2010-01-07 CA CA2749730A patent/CA2749730C/en not_active Expired - Fee Related
- 2010-01-15 TW TW099101001A patent/TW201036971A/zh unknown
-
2011
- 2011-06-30 IL IL213857A patent/IL213857A0/en unknown
- 2011-07-11 ZA ZA2011/05085A patent/ZA201105085B/en unknown
- 2011-07-14 SV SV2011003973A patent/SV2011003973A/es unknown
- 2011-07-14 CL CL2011001712A patent/CL2011001712A1/es unknown
- 2011-07-14 TN TN2011000349A patent/TN2011000349A1/fr unknown
-
2014
- 2014-03-18 US US14/217,664 patent/US20140288079A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG172841A1 (en) | 2011-08-29 |
| ZA201105085B (en) | 2012-09-26 |
| AU2010205931A1 (en) | 2011-07-28 |
| TN2011000349A1 (en) | 2013-03-27 |
| WO2010081647A2 (en) | 2010-07-22 |
| MA32967B1 (fr) | 2012-01-02 |
| KR20110117655A (ko) | 2011-10-27 |
| SV2011003973A (es) | 2011-12-06 |
| MX2011007515A (es) | 2011-08-12 |
| JP5780430B2 (ja) | 2015-09-16 |
| CA2749730A1 (en) | 2010-07-22 |
| US20140288079A1 (en) | 2014-09-25 |
| EA201170942A1 (ru) | 2012-02-28 |
| US20120022028A1 (en) | 2012-01-26 |
| IL213857A0 (en) | 2011-07-31 |
| EP2387404A2 (en) | 2011-11-23 |
| JP2012515176A (ja) | 2012-07-05 |
| ES2493718T3 (es) | 2014-09-12 |
| CL2011001712A1 (es) | 2012-04-09 |
| CA2749730C (en) | 2017-02-14 |
| EP2387404B1 (en) | 2014-06-25 |
| CN102316870A (zh) | 2012-01-11 |
| TW201036971A (en) | 2010-10-16 |
| WO2010081647A3 (en) | 2010-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1006869A2 (pt) | estimuladores de sgc ou ativadores da sgc em combinação com inibidores da pde5 para o tratamento de disfunção erétil | |
| IL230683A0 (en) | dpp-iv inhibitors for use in the treatment of nafld | |
| BRPI1013698A2 (pt) | métodos para tratamento com o uso de terapia de combinação | |
| ME02207B (me) | UPOTREBA sGC STIMULATORA, sGC AKTIVATORA, POJEDINAČNO I U KOMBINACIJI SA PDE5 INHIBITORIMA ZA TRETMAN SISTEMSKE SKLEROZE (SSc) | |
| HK1170737A1 (zh) | 萘啶衍生物及其作為激酶抑制劑的用途 | |
| BRPI1011066A2 (pt) | "pirazolopirimidinas e heterociclos relacionados como inibidores de quinase | |
| SMT201500286B (it) | STIMOLATORI DI sGC O ATTIVATORI DI sGC DA SOLI O IN COMBINAZIONE CON INIBITORI DI PDE5 PER IL TRATTAMENTO DELLA FIBROSI CISTICA | |
| IL220086A0 (en) | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors | |
| BR112012004149A2 (pt) | terapia de combinação com composições de nanopartículas de taxano e inibidores de hedgehog | |
| ZA201001193B (en) | 2-anilinopurin-8-ones as inhibitors of TTK/MPS1 for the treatment of proliferative disorders | |
| HK1153926A1 (en) | Purin derivatives for use in the treatment of fab-related diseases fab- | |
| HUE050862T2 (hu) | Merevedési zavar és más indikációk kezelése | |
| IL207127A0 (en) | Aldh-2 inhibitors in the treatment of addiction | |
| HK1244706A1 (zh) | 用於治療勃起功能障礙的組成物及方法 | |
| HK1256479A1 (zh) | 在治療癌症中grn163l用作端粒酶抑制劑 | |
| GB201211237D0 (en) | CDK5 inhibitors and therapeutic uses thereof | |
| EP2456437A4 (en) | COMBINATION THERAPY FOR TAUOPATHIES | |
| ES2389424B1 (es) | Procedimiento para la visualizacion de superficies en el cuerpo humano. | |
| IT1391451B1 (it) | Preparato per il trattamento della disfunzione erettile | |
| ES1071986Y (es) | Dispositivo para el tratamiento de la precombustion | |
| TH114429B (th) | การใช้แบคทีเรียแลคติกในการรักษาหรือป้องกันโรคผิวหนังอักเสบ | |
| UA36331U (ru) | Применение рисперидона как средства для лечения опиоидной зависимости | |
| TH141460A (th) | การใช้สารกระตุ้น sGC, สารปลุกฤทธิ์ sGC เพียงสารเดียวและใช้ร่วมกับสารยับยั้ง PDE5 เพื่อรักษาโรคหนังแข็ง (SSc) (The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES. |
|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |